7.16 0.00 (0.00%)
After hours: 5:12PM EST
|Bid||7.06 x 800|
|Ask||7.95 x 900|
|Day's Range||6.96 - 7.80|
|52 Week Range||3.74 - 38.82|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.60|
The abstract, “Serlopitant Reduced Pruritus Associated with Psoriasis in Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial” will be presented as part of Late Breaking Research: Clinical Trials on Saturday, March 2 between 1:00 p.m. and 4:00 p.m. in Ballroom A. In addition, a second abstract, “Improvement of Itch and Pain in Patients with Prurigo Nodularis Treated with Serlopitant: Secondary analysis of Phase 2 Clinical Trial” was accepted as an oral presentation and online e-poster. Presentations will be held on Friday, March 1 and Saturday, March 2.
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
REDWOOD CITY, Calif., Jan. 15, 2019 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the.
In January 2018, Menlo Therapeutics Inc. (MNLO) completed its IPO, selling over 8 million shares of common stock at $17.00 per share. The plaintiff claims that in its registration statement, Menlo Therapeutics Inc. stated that if the results of its Phase 2 clinical trials for the treatment of pruritus are promising, the company would "rapidly advance into Phase 3 clinical trials" and would use the net proceeds from the IPO to fund such trials.
Menlo Therapeutics Inc. (NASDAQ:MNLO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MNLO Read More...
To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (MNLO) pursuant or traceable to the Company’s Initial Public Offering closed on January 29, 2018. If you purchased or otherwise acquired Menlo securities pursuant to the initial public offering, your rights may be affected by this action. In its January 2018 IPO, Menlo issued over 8 million shares at $17 per share, raising over $136 million in gross proceeds.
SAN DIEGO, CA / ACCESSWIRE / December 17, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) over alleged ...
Is Menlo Therapeutics Inc. (NASDAQ:MNLO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access […]
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Menlo Therapeutics Inc. (MNLO) filed a class action complaint against the company's officers and directors for alleged violations of the Securities Act of 1933 in connection with Menlo's January 29, 2018 initial public offering ("IPO"). Menlo, a late-stage biopharmaceutical company, develops and commercializes serlopitant for the treatment of itching associated with dermatologic conditions in the United States.
NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, Dec. 11, 2018 -- Levi & Korsinsky announces it has commenced an investigation of Menlo Therapeutics, Inc. (“Menlo” or “the Company”) (NASDAQGS: MNLO) concerning.
The trial successfully met the secondary endpoint of WI-NRS responder rate at week 4. At week 4, 21% of patients treated with serlopitant achieved a 4-point or greater improvement on the WI-NRS vs. 11% of patients treated with placebo (p=0.039). Assessment of the secondary endpoints of the absolute change in WI-NRS from baseline to day 7 and day 3 for serlopitant compared to placebo showed a greater numerical, but not statistically significant, improvement for the serlopitant group. At every assessed time point in the trial (daily in week 1 and average weekly scores through week 8), the serlopitant treated group demonstrated greater numerical improvement than the placebo group in both the WI-NRS 4-point responder analysis and in the mean change in WI-NRS from baseline. Serlopitant was well-tolerated in this clinical trial. No serious adverse events were reported for serlopitant treated patients. Treatment-emergent adverse events assessed as likely related to treatment were observed with similar frequency in both groups (4.0% for placebo and 4.9% for serlopitant). The consolidated safety summary for serlopitant now includes more than 1,600 evaluable patients, including patients who have received treatment for up to one year.
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
RADNOR, PA / ACCESSWIRE / November 14, 2018 / Kaskela Law LLC is investigating Menlo Therapeutics Inc. (NASDAQ: MNLO) ("Menlo" or the "Company") on behalf of investors. Menlo is a late-stage ...
NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Menlo Therapeutics Inc. (''Menlo'' or the ''Company'') (NASDAQ: ...
NEW YORK , Oct. 23, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics ...
Menlo Therapeutics' (MNLO) sole pipeline candidate, serlopitant, fails to meet endpoint in a phase II study in refractory chronic cough patients. Study to be terminated.